Optovue receives FDA clearance of iCam

Article

Optovue has received 510(k) clearance for its iCam non-mydriatic, compact fundus camera.

 

Fremont, CA-Optovue has received 510(k) clearance for its iCam non-mydriatic, compact fundus camera.

The iCam produces 45-degree color fundus images of the eye as well as external ocular structures. iCam includes a variety of functions and features that produce high-quality image documentation and management of ocular health. A 12-bit CCD image sensor provides deep, rich colors with lower noise than 8-bit CMOS sensors. An LED light source is used for reduced peak light energy to the eye as well as longer life.

The device includes simple joystick control, focusing and positioning aids to expedite the photography process while an easy user interface enables image review and EMR communication.

iCam is expected to release to the U.S. market in Q2, followed by a global release.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.